Scarica l'app Stockscreener
7.24
0.42%
0.03
Dopo l'orario di chiusura:
7.27
0.03
+0.41%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Eyepoint Pharmaceuticals Inc Borsa (EYPT) Ultime notizie
EyePoint advances with Duravyu Phase III trial - Yahoo
H.C. Wainwright maintains Buy on EyePoint with $22 target By Investing.com - Investing.com India
H.C. Wainwright maintains Buy on EyePoint with $22 target - Investing.com
EyePoint Pharmaceuticals (NASDAQ:EYPT) shareholders are up 29% this past week, but still in the red over the last year - simplywall.st
Biggest Companies on Nasdaq EyePoint Pharmaceuticals Insights by Kalkine - Kalkine Media
Analyst Expectations For EyePoint Pharmaceuticals's Future - Benzinga
EyePoint Pharmaceuticals (EYPT) Reiterates Buy Rating with $22 Price Target | EYPT Stock News - GuruFocus
EyePoint Pharmaceuticals (EYPT) Reiterates Buy Rating with $22 P - GuruFocus
EyePoint Announces Participation at Upcoming Investor Conferences - The Manila Times
EyePoint Secures Triple Conference Spotlight: Goldman Sachs, Jefferies, and Guggenheim Healthcare Events - Stock Titan
EyePoint at Stifel Forum: Strategic Advances in Ophthalmology By Investing.com - Investing.com Canada
JPMorgan maintains EyePoint stock Overweight with $26 target By Investing.com - Investing.com India
JPMorgan maintains EyePoint stock Overweight with $26 target - Investing.com
Eyepoint Completes Enrollment In Pivotal Phase 3 Lugano Trial Of Duravy For Treatment Of Wet Age-Related Macular Degeneration - marketscreener.com
EyePoint (EYPT) Surpasses Enrollment Goal in Key Phase 3 Trial | - GuruFocus
EyePoint Completes Enrollment for DURAVYU Phase 3 Trial - TipRanks
EyePoint Pharmaceuticals Reports Rapid Enrollment Progress in Phase 3 LUGANO Trial of DURAVYU™ for Wet AMD Treatment - Nasdaq
EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration - The Manila Times
EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors - The Globe and Mail
Insider Buying: Karen Zaderej Acquires Additional Shares of EyeP - GuruFocus
Insider Buying: Karen Zaderej Acquires Additional Shares of EyePoint Pharmaceuticals Inc (EYPT) - GuruFocus
EyePoint Pharmaceuticals (EYPT) Target Price Lowered by Mizuho Analyst | EYPT Stock News - GuruFocus
EyePoint (EYPT) Faces Price Target Reduction by Mizuho | EYPT St - GuruFocus
EyePoint price target lowered to $26 from $30 at Mizuho - TipRanks
Mizuho Cuts Price Target on EyePoint Pharmaceuticals to $26 From $30, Keeps Outperform Rating - marketscreener.com
Eyepoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
EyePoint (EYPT) Grants Stock Options to New Employees as Inducem - GuruFocus
EyePoint (EYPT) Grants Stock Options to New Employees as Inducement Awards | EYPT Stock News - GuruFocus
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | EYPT Stock News - GuruFocus
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
EyePoint Awards Major Stock Options Package: 7 New Hires Receive 136,700 Shares at $5.72 - Stock Titan
Mizuho cuts EyePoint Pharmaceuticals target to $26 By Investing.com - Investing.com India
Mizuho cuts EyePoint Pharmaceuticals target to $26 - Investing.com
Balyasny Asset Management L.P. Grows Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - MarketBeat
(EYPT) Technical Data - news.stocktradersdaily.com
New Forecasts: Here's What Analysts Think The Future Holds For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Yahoo Finance
Earnings Beat: EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo
Eyepoint projects DURAVYU Phase 3 enrollment completion by H2 2025 amid strong clinical trial momentum - MSN
EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates - MSN
EyePoint Pharmaceuticals (EYPT): Analyst Maintains Buy Rating, Lowers Price Target | EYPT Stock News - GuruFocus
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q1 2025 Earnings Call Transcript - Insider Monkey
EyePoint Pharma’s Promising Q1 2025 Financial Results - TipRanks
EyePoint Pharmaceuticals: Q1 Earnings Snapshot - Midland Daily News
EyePoint Pharmaceuticals (EYPT) Reports Growth Amidst Trial Developments - GuruFocus
Transcript : EyePoint Pharmaceuticals, Inc., Q1 2025 Earnings Call, May 07, 2025 - marketscreener.com
EyePoint Pharmaceuticals Q1 2025 Earnings Preview - MSN
Earnings call transcript: EyePoint Pharmaceuticals Q1 2025: Revenue Surges - Investing.com
EyePoint Pharmaceuticals (EYPT) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
EyePoint (EYPT) Sees Strong Q1 Revenue Growth and Advances in DURAVYU Trials | EYPT Stock News - GuruFocus
EyePoint Pharmaceuticals Inc Surpasses Revenue Estimates with $24.5 Million in Q1 2025, EPS of ($0.65) Slightly Beats Expectations - GuruFocus
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):